Dental and medical products company Henry Schein (NASDAQ: HSIC) met Wall Street’s revenue expectations in Q3 2026, with sales up 4% year on year to $3.47 billion. Its non-GAAP profit of $1.37 per share was 0.9% above analysts’ consensus estimates.

Is now the time to buy HSIC? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Henry Schein’s third quarter was marked by solid execution in its core dental business, but the market responded negatively to the results. Management attributed the quarter’s performance to strong volume-driven growth in U.S. dental merchandise, supported by market share gains in both private practices and emerging dental service organizations. CEO Fred Lowery stated, “What’s really driving it is our company-owned products, exclusive products like Curodont, and great commercial execution.” At the same time, a one-time tariff refund provided a meaningful boost to non-GAAP earnings, which exceeded analyst expectations. Management remained focused on its value creation initiatives and highlighted ongoing investments to support future growth.

Looking ahead, Henry Schein raised its non-GAAP earnings guidance, underpinned by continued investment in growth areas and further operational streamlining. Management identified targeted spending in the fourth quarter to win new customers and deepen relationships, aiming for sustainable double-digit earnings growth in the coming year. CFO Ron South commented, “These are scalable and sustainable activities that give us confidence we can continue to achieve double-digit growth.” The company is also betting on new technology-enabled solutions in its dental software portfolio and expects product innovation—such as the Versalis implant—to drive incremental gains. Management acknowledged ongoing cost pressures but expressed confidence that pricing strategies and private label expansion can offset inflation going forward.

Key insights from management’s remarks

Management attributed quarterly performance to volume-driven share gains in dental, benefits from tariff refunds, and growth-focused investments, while calling out stable core markets and ongoing margin initiatives.

• Dental volume leads growth: U.S. dental merchandise sales rose primarily due to higher volumes rather than price increases, reflecting share gains in both private practices and emerging dental service organizations (DSOs). Management emphasized that company-owned and exclusive products, such as Curodont, were key contributors.
• Tariff refund boosts profitability: A $28 million one-time tariff refund flowed through cost of goods sold, with $20 million benefiting the distribution segment and $8 million the specialty segment, providing a notable uplift to non-GAAP earnings per share for the quarter.
• Value creation initiatives on track: Management highlighted progress on its value creation plan, targeting $200 million in operating income improvements by the end of 2026. Initiatives include streamlining operations, expanding shared services, and investing in supply chain and AI-enabled tools to improve efficiency and margins.
• Technology adoption accelerates: Henry Schein One, the company’s dental software division, saw continued momentum in cloud-based platforms such as Dentrix Ascend and Dentally, now reaching nearly 13,500 subscribers and growing by about 200 net new customers per month. These platforms integrate AI features that support workflow automation, collections, and patient engagement.
• Medical segment mixed: While Home Solutions delivered double-digit growth, the broader U.S. medical business was offset by lower sales of point-of-care diagnostics and vaccines. Management expects a stronger flu season in the fourth quarter to help medical sales rebound.

Drivers of future performance

Henry Schein’s outlook is anchored by continued investment in dental technology, expansion of its company-owned brands, and ongoing cost discipline, though management flagged persistent inflation and some market uncertainties.

• Selective investments for growth: Management is allocating resources towards converting episodic customers into long-term clients, expanding exclusive product offerings, and supporting cloud-based dental software adoption. These actions are intended to solidify share gains and drive higher-margin sales, especially as the company leverages data-driven insights from its technology platforms.
• Margin improvement focus: Ongoing value creation initiatives—including further centralization, shared services, and portfolio streamlining—aim to generate $125 million run-rate operating income improvement by year-end. Management stated these projects are “scalable and sustainable,” with expectations of continued benefits into 2027.
• Inflation and market headwinds: While management believes pricing strategies and private label growth can offset inflation in cost of goods sold, they acknowledged ongoing headwinds in discretionary dental procedures, some volatility in point-of-care diagnostics, and macroeconomic pressures in select geographies like Brazil. The company expects core medical and dental markets to remain steady but is monitoring these risks closely.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will watch (1) evidence that dental volume and share gains are sustainable, especially as targeted investments are deployed; (2) execution of margin expansion via shared services and portfolio streamlining; and (3) adoption rates of cloud-based dental software and new product launches, such as Versalis. Shifts in medical segment demand, especially in Home Solutions and diagnostics, will also be key indicators of ongoing momentum.

Henry Schein currently trades at $82.46, down from $86.62 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.